Probiotics
Microbiome, live cultures and functional health.
Latest Probiotics news
The Microbiome Comes of Age
Read at WholeFoods Magazine →Gut bacteria convert nitrate and iron into heart-protective molecules, research finds
Read at Nutrition Insight →How gut bacteria linked to muscle strength could help fight ageing
Read at The Independent →This Gut Health Approach May Help With A Common Mental Health Issue
Read at MindBodyGreen →The 2 underrated foods dietitians wish you would eat for better gut health and longevity
Read at Business Insider →8 Fermented Foods That May Help Support Gut Health
Read at AOL.com →From the knowledge base
What did we learn from Big Pharma’s Q2 results?
Fierce editors break down Big Pharma’s second-quarter results, from AI and new leadership to the oral GLP-1 race and potential new blockbusters.
Regulatory tracker: J&J scores EU approval for Tecvayli-Darzalex combo
In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansions into key geographies and new indications. Some of these updates may not meet the bar for standalone stories, but we think they are still worth mentioning.
The Oral GLP-1 Tracker: Novo's Wegovy pill back on track as Lilly's momentum slows
Fierce Pharma is launching the weekly Oral GLP-1 Tracker, leveraging analysts’ notes and IQVIA data to monitor prescription trends and shifting market shares as Novo Nordisk's Wegovy pill and Eli Lilly's Foundayo vie to become the go-to oral weight-loss solution for millions.
Lundbeck continues neuroscience evolution as CEO keeps company ‘punching above its weight’
Almost three years into his tenure as Lundbeck’s CEO, Charl van Zyl is confident the company can prove its mettle as a “neuroscience challenger” capable of “punching above its weight.”
Boehringer places phase 1 study of investigational drug on hold to examine ‘safety event’
Boehringer Ingelheim has suspended a phase 1 trial of an investigational small molecule drug while it seeks to understand a “safety event,” although the German pharma isn't shedding light on the nature of the incident for now.
Why Pheast’s CEO has no regrets about transparent approach to R&D despite competitors circling
Pheast Therapeutics may have learned the hard way about the risks of competitors getting a glimpse of your heard-earned discoveries, but the immuno-oncology startup is so far sticking to its transparent approach.